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Autophagy fights disease through cellular
self-digestion
Noboru Mizushima1, Beth Levine2, Ana Maria Cuervo3 & Daniel J. Klionsky4
Autophagy, or cellular self-digestion, is a cellular pathway involved in protein and organelle degradation, with an astonishing
number of connections to human disease and physiology. For example, autophagic dysfunction is associated with cancer,
neurodegeneration, microbial infection and ageing. Paradoxically, although autophagy is primarily a protective process
for the cell, it can also play a role in cell death. Understanding autophagy may ultimately allow scientists and clinicians to
harness this process for the purpose of improving human health.
A
t first glance, it may seem perplexing that a process of
cellular self-eating could be beneficial. In its simplest form,
however, autophagy probably represents a single cell’s
adaptation to starvation—if there is no food available in
the surroundings, a cell is forced to break down part of its own reserves
to stay alive until the situation improves. In single-cell organisms such
as yeasts, this starvation response is one of the primary functions of
autophagy, but in fact this role extends up through to humans. For
example, even on a day-to-day basis, autophagy is activated between
meals in organs such as the liver to maintain its metabolic functions,
supplying amino acids and energy through catabolism1,2.
There are various types of autophagy, including micro- and
macroautophagy, as well as chaperone-mediated autophagy
(CMA), and they differ in their mechanisms and functions
(Fig. 1)3,4. Both micro- and macroautophagy have the capacity to
engulf large structures through both selective and non-selective
mechanisms, whereas CMA degrades only soluble proteins, albeit
in a selective manner. The capacity for large-scale degradation is
important in autophagic function, but it carries a certain risk,
because unregulated degradation of the cytoplasm is likely to be
lethal. On the other hand, basal levels of autophagy are important
for maintaining normal cellular homeostasis. Thus, it is important
that autophagy be tightly regulated (Fig. 2) so that it is induced when
needed, but otherwise maintained at a basal level. Although a com-
plete picture of autophagy regulation is not available, many aspects
have been covered in recent reviews5–8.
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Figure 1 | Different types of autophagy. Microautophagy refers to the
sequestration of cytosolic components directly by lysosomes through
invaginations in their limiting membrane. The function of this process in
higher eukaryotes is not known, whereas microautophagy-like processes in
fungi are involved in selective organelle degradation. In the case of
macroautophagy, the cargoes are sequestered within a unique double-
membrane cytosolic vesicle, an autophagosome. Sequestration can be either
nonspecific, involving the engulfment of bulk cytoplasm, or selective,
targeting specific cargoes such as organelles or invasive microbes. The
autophagosome is formed by expansion of the phagophore, but the origin of
the membrane is unknown. Fusion of the autophagosome with an endosome
(not shown) or a lysosome provides hydrolases. Lysis of the autophagosome
inner membrane and breakdown of the contents occurs in the autolysosome,
and the resulting macromolecules are released back into the cytosol through
membrane permeases. CMA involves direct translocation of unfolded
substrate proteins across the lysosome membrane through the action of a
cytosolic and lysosomal chaperone hsc70, and the integral membrane
receptor LAMP-2A (lysosome-associated membrane protein type 2A).
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Both the non-selective and selective nature of autophagy, as well as
basal and induced levels, are important in regard to the role of this
process in human health and disease. Perhaps the most fundamental
point is that either too little or too much autophagy can be deleteri-
ous, a complexity seen in its dual role in cytoprotection and cell
death. With the identification of many autophagy-related (ATG)
genes and improved methods for monitoring this process, future
research on this topic should continue to progress.
Autophagy in cell survival and cell death
The pro-survival function of autophagy has been demonstrated at the
cellular and organismal level in different contexts, including during
nutrient and growth factor deprivation, endoplasmic reticulum
stress, development, microbial infection, and diseases characterized
by the accumulation of protein aggregates8–11. This pro-survival
function is generally believed to be adaptive, but, in the context of
cancer, is potentially maladaptive12. Metabolic stress is a common
feature of the tumour microenvironment and most chemotherapeu-
tic agents induce cellular stress. Thus, an area of intense investigation
is whether autophagy-dependent survival should be blocked in these
settings to promote tumour-cell death13.
An apparent conundrum is that autophagy acts both in cytoprotec-
tion and in cell death. In response to most forms of cellular stress,
autophagy plays a cytoprotective role, because ATG gene knockdown/
knockout accelerates rather than delays cell death9,11. However, in
certain settings where there is uncontrolled upregulation of autophagy
(for example, overexpression of the autophagy protein Beclin 1 in
mammalian cells14, and Atg1 overexpression in Drosophila15), auto-
phagy can lead to cell death, possibly through activating apoptosis15 or
possibly as a result of the inability of cells to survive the non-specific
degradation of large amounts of cytoplasmic contents. Notably, many
examples of ATG-gene-dependent cell death occur in cells deficient in
apoptosis9, suggesting that autophagy, as a route to cell death, may be a
choice of last resort. One general caveat to these types of studies is that
the overexpression or knockout of a single ATG gene could have
unknown indirect effects beyond autophagy.
Autophagic programmed cell death was originally described in
tissues undergoing active development. Yet, not only is there no
evidence that ATG gene inhibition prevents this death, but the
opposite may be true. Nematodes lacking bec-1, the Caenorhabditis
elegans orthologue of ATG6/beclin 1, and mice lacking beclin 1 or atg5
display increased numbers of apoptotic cells in embryonic tissues,
arguing against a requirement for the autophagic machinery in
developmental programmed cell death16,17. It may, however, be pre-
mature to conclude that autophagy deficiency results in the increased
generation of apoptotic cells during development, because the ATG
machinery also has a role in the heterophagic removal of apoptotic
corpses16. In mature animals with tissue-specific ATG gene knockout,
there is perhaps clearer evidence of an anti-apoptotic function of
autophagy in vivo18–20.
The cross-talk between autophagy, a pathway that functions pri-
marily in cell survival, and apoptosis, a pathway that invariably leads
to cell death, is complex. The two pathways are regulated by common
factors, they share common components, and each can regulate and
modify the activity of the other9,11. Many signals originally studied in
the context of apoptosis activation induce autophagy, whereas signals
that inhibit apoptosis also inhibit autophagy5–7. Anti-apoptotic pro-
teins, such as Bcl-2 family members, inhibit Beclin 114, and pro-
apoptotic factors, such as BH3-only proteins, disrupt this inhibitory
interaction and thereby activate autophagy21. Another link between
the autophagic machinery and apoptosis is the observation that Atg5
can undergo calpain-mediated cleavage to generate a pro-apoptotic
fragment that functions in the intrinsic mitochondrial death path-
way22. These examples may represent only the tip of the iceberg, as we
clearly are just beginning to understand the intricate molecular inter-
play between autophagy and apoptosis. However, it does seem likely
that the coordinated regulation of ‘self-digestion’ by autophagy and
‘self-killing’ by apoptosis may underlie diverse aspects of develop-
ment, tissue homeostasis and disease pathogenesis.
Neurodegeneration
Growing evidence reveals that alterations in autophagy occur in
many human diseases. Here we discuss only those disorders in which
autophagy malfunction has been shown to contribute to their patho-
genesis (Fig. 3). As mentioned above, autophagy occurs at basal,
constitutive levels and recent studies have highlighted the import-
ance of basal autophagy in intracellular quality control. The demand
for basal autophagy differs among tissues; it is particularly important
in the liver and in other tissues where the cells, such as neurons and
myocytes, do not divide after differentiation18,19,23–25. In contrast to
conventional atg5, atgatg5 and beclin 1 knockout mice, which die
during embryogenesis or the neonatal period1,23,26–29, those with
neural-tissue-specific knockouts of these genes survive the postnatal
starvation period. However, these mice develop progressive motor
deficits and display abnormal reflexes, and ubiquitin-positive inclu-
sion bodies accumulate in their neurons18,19. Although the levels of
autophagosomes detected in neurons are very low under normal and
even starvation conditions30,31, these studies strikingly show that con-
stitutive turnover of cytosolic contents by autophagy is indispens-
able, even in the absence of expression of any disease-associated
mutant proteins.
Despite the important function of basal autophagy in healthy
individuals, the requirement for autophagy is even more evident
under disease conditions. Recent studies reveal that degradation of
disease-related mutant proteins is highly dependent on autophagy, in
addition to the ubiquitin–proteasome system. Examples include


















Figure 2 | A simplified model of autophagy regulation. Macroautophagy
occurs at a basal level and can be induced in response to environmental
signals including nutrients and hormones, and also microbial pathogens.
The best-characterized regulatory pathway includes a class I PI3K and TOR,
which act to inhibit autophagy, although the mechanism is not known. A
class III PI3K is needed for activation of autophagy. TOR activity is probably
regulated in part through feedback loops to prevent insufficient or excessive
autophagy. For example, p70S6 kinase is a substrate of TOR that may act to
limit TOR activity, ensuring basal levels of autophagy that are critical for
homeostasis. Proteins in green and pink are stimulatory and inhibitory for
autophagy, respectively. Dashed lines indicate possible regulatory effects.
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neurodegenerative diseases such as Huntington’s disease and
spinocerebellar ataxia, and mutant forms of a-synuclein that cause
familial Parkinson’s disease32–34. CMA also participates in wild-type
a-synuclein degradation, but mutant forms of a-synuclein block the
lysosomal receptor, resulting in general CMA inhibition35. The affec-
ted cells attempt to compensate for the CMA blockage by upregulat-
ing macroautophagy, which guarantees cell survival but renders the
cells more susceptible to stressors4.
Considering all of the available data, there is no doubt that auto-
phagy has a beneficial effect of protecting against neurodegeneration;
however, how autophagy can prevent neurodegeneration is not com-
pletely understood. One hypothesis is that autophagy eliminates pro-
tein aggregates or inclusion bodies, possibly in a directed manner36,37.
One possible adaptor is p62/sequestosome-1 (SQSTM1)36. Almost all
protein aggregates are decorated with ubiquitin, and SQSTM1 has
both LC3-binding (the mammalian homologue of the autophagy-
related protein Atg8) and ubiquitin-binding domains, allowing it to
mediate the recognition of protein aggregates by a protein (LC3) in the
membrane of the forming autophagosome36,38. Furthermore, proper
turnover of p62 by autophagy is critical to prevent spontaneous
aggregate formation39.
However, direct degradation of aggregates by autophagy is some-
how contradictory to the recent hypothesis that the generation of
protein aggregates is a protective mechanism40,41. Rather, the primary
target of autophagy seems to be diffuse cytosolic proteins, not inclu-
sion bodies themselves, suggesting that inclusion body formation in
autophagy-deficient cells is an event secondary to impaired general
protein turnover18. However, it is still possible that misfolded pro-
teins in soluble or oligomeric states could be preferentially recog-
nized by autophagosomal membranes, which might also be mediated
by ubiquitin–p62–LC3 interactions.
Alterations of autophagy have also been observed in Alzheimer’s
disease, but in this case the contribution of autophagy may not be
as simple as in other types of neurodegeneration. For example,
autophagosome-like structures accumulate in dystrophic neurites
of Alzheimer’s disease patients and model mice, probably owing to
impairment of autophagosome maturation into autolysosomes
(Fig. 1)42. Surprisingly, the toxic proteolytic product Ab can be pro-
duced within these partially degraded compartments because the Ab
precursor protein, APP, and the protease responsible for its cleavage,
are both present in the endoplasmic reticulum sequestered in these
structures42. Therefore, one hypothesis is that impaired autophagic
flux provides a novel site for Ab peptide production.
It is reasonable to assume that autophagy could be a therapeutic
target for treatment of these neurodegenerative diseases because of its
protective role43. For example, upregulation of autophagy by the regu-
latory protein kinase complex Target of Rapamycin (TOR) inhibitors
such as rapamycin and its analogue CCI-779 protects against neuro-
degeneration seen in polyglutamine disease models in Drosophila
and mice44. Recently, small-molecule enhancers of rapamycin were
identified45. These improve the clearance of mutant huntingtin and
a-synuclein, and protect against neurodegeneration in a fruit-fly
Huntington’s disease model. Importantly, the effects of small-
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Figure 3 | The role of autophagy in human disease. Degradation, in
particular through autophagy and the proteasome, is important in cellular
physiology. Autophagy can act as a cytoprotective mechanism to prevent
various diseases, and dysfunctional autophagy leads to pathology. In some
cases, however, autophagy can be deleterious; for example, some microbes
subvert autophagy for replication, and the cytoprotective action can allow
cancer cells to resist anti-cancer treatments.
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it possible to use them in combination with rapamycin for therapeutic
purposes. In any attempt at manipulating autophagy therapeutically,
however, it is important to take into account the dynamic nature of the
changes that occur in the autophagic system during the pathogenic
course of a disease (Fig. 3).
Innate and adaptive immunity
The disposal of intracellular organisms, similar to cellular organelles,
represents a steric challenge for cellular degradative pathways that
may be uniquely met by autophagy. The same autophagic machinery
used to selectively capture cellular organelles is used for the selective
delivery of microorganisms to lysosomes in a process termed xeno-
phagy46. In mammals (and perhaps other metazoan organisms), the
role of autophagy in antimicrobial defence probably extends beyond
the direct elimination of pathogens. A growing number of studies
indicate a role for autophagy in delivery of microbial antigenic
material to the innate and adaptive immune system, as well as in
maintaining lymphocyte homeostasis47,48 (Fig. 3).
Xenophagy can target extracellular bacteria that invade intracellu-
larly, bacteria and parasites that reside in the cytosol, phagosomes, or
pathogen-containing vacuoles, as well as newly synthesized virions
during their exit from the nucleus through the cytoplasm47,49. The cell
biology of xenophagy is less well-studied than classical autophagy
and despite the overlap in molecular components required for the
two processes, it is not yet clear whether the membranes engulfing
microorganisms have a biogenesis similar or different to that of clas-
sical autophagosomes. Pathogen-containing LC3-positive compart-
ments can be considerably larger than classical autophagosomes
consisting exclusively of cellular constituents47, indicating a plasticity
of the autophagic process that permits it to adapt to the need to
engulf microbes that are larger than its own organelles, a capacity
that reflects the unique mechanism of autophagosome formation
(Fig. 1). Although xenophagy appears to be primarily a selective form
of autophagy, almost nothing is known about how microbes (or
membranous compartments containing microbes) are recognized
by the autophagic machinery.
Beyond its direct role in pathogen elimination, autophagy may
exert cytoprotective functions in infected cells and also mediate traf-
ficking events required for innate and adaptive immunity. In the case
of certain RNA viral infections, autophagy is required for the delivery
of viral nucleic acids to the endosomal toll-like receptor TLR7, and
subsequent activation of type I interferon signalling47. The autopha-
gic machinery is also used for the major histocompatibility complex
(MHC) class II presentation of certain endogenously synthesized
viral antigens47. Not only does the autophagic machinery function
in innate and adaptive immunity, but several innate and adaptive
immune mediators involved in intracellular pathogen control stimu-
late autophagy47.
Given the diverse roles of autophagy in innate and adaptive immu-
nity, it is not surprising that many pathogens have devised strategies to
outsmart autophagy. Some intracellular bacteria and viruses co-opt
the autophagic machinery to use Atg protein-dependent dynamic
membrane rearrangements to their own replicative advantage49,50.
More commonly, successful intracellular pathogens modulate the sig-
nalling pathways that regulate autophagy or block the membrane
trafficking events required for autophagy-mediated pathogen delivery
to the lysosome47. Notably, in certain settings, microbial evasion of
autophagy may be essential for microbial pathogenesis. For example,
fatal herpes simplex virus encephalitis requires inhibition of the
Beclin 1 autophagy protein by a virus neurovirulence protein51.
Thus, the selective disruption of interactions between microbial viru-
lence factors and their targeted host autophagy proteins may help
reduce infection-induced pathology.
Other postulated roles of autophagy in immunity that warrant
further scientific attention include T-cell homeostasis, central and
peripheral tolerance induction, and the prevention of unwanted
inflammation and autoimmunity47. We also note that several recent
genome-wide scans have uncovered strong associations between a
non-synonymous single nucleotide polymorphism in the autophagy
gene ATG16L1 as well as in the autophagy-stimulatory immunity-
related GTPase IRGM, and susceptibility to Crohn’s disease, an
inflammatory disease of the intestine13. These associations suggest
an intriguing potential role for autophagy deregulation in the patho-
genesis of Crohn’s disease. However, it is not known whether the
ATG16L variant is defective in autophagy function and whether this
genetic association is indicative of a mechanistic link between auto-
phagy impairment and Crohn’s disease pathogenesis. Studies in tar-
geted mutant mice with a knock-in T300A mutation in ATG16L1
should help clarify these important questions.
Cancer
Cancer is one of the first diseases genetically linked to autophagy
malfunction12,13. The ATG gene beclin 1 is monoallelically deleted
in 40–75% of cases of human breast, ovarian, and prostate cancer.
This is probably mechanistically important in tumorigenesis, because
mice with heterozygous disruption of beclin 1 have decreased auto-
phagy and are more prone to the development of spontaneous
tumours including lymphomas, lung carcinomas, hepatocellular car-
cinomas, and mammary precancerous lesions27,29. Further, immor-
talized kidney and mammary epithelial cells derived from beclin 1
heterozygous-deficient mice are more tumorigenic when trans-
planted in vivo. Other components that enhance the autophagic
activity of the Beclin 1/class III phosphatidylinositol 3-kinase (PI3K)
complex, including ultraviolet irradiation resistance-associated gene
(UVRAG), Ambra1 and Bif-1 may also play a role in cell growth
control and/or tumour suppression26,28. In animal models, additional
ATG genes including atg4c also exert tumour suppressor effects52,
suggesting that tumour suppression may be a shared property of
autophagy proteins that act at different steps of the pathway (Fig. 3).
Beyond a role for ATG genes in tumour suppression, there is accu-
mulating evidence that autophagy signalling regulation is tightly
linked to oncogenic signalling. Several commonly activated onco-
genes (for example, those encoding class I PI3K, PKB, TOR, Bcl-2)
inhibit autophagy, whereas commonly mutated or epigenetically
silenced tumour suppressor genes (such as those encoding p53,
PTEN, DAPk, TSC1/TSC2) stimulate autophagy5.
These genetic links between defects in autophagy regulation or
execution and cancer suggest that autophagy is a true tumour sup-
pressor pathway. However, the mechanisms by which it functions
in tumour suppression remain largely undetermined. Autophagy
may directly regulate cell growth, functioning as a brake to prevent
cells from inappropriately dividing in the absence of appropriate
trophic support (even though it may promote cell survival in this
setting)13. The increased frequency of mitochondrial DNA mutations
in autophagy-deficient yeast suggests that mitochondrial turnover
mediated by basal autophagy may prevent genotoxic stress and
DNA damage12,13. Indeed, recent studies strikingly reveal that both
beclin 1 and atg5 function as ‘guardians’ of the cellular genome.
Immortalized epithelial cells with mono-allelic or bi-allelic loss of
beclin 1 or atg5, respectively, display increased DNA damage, gene
amplification, and aneuploidy, especially during ischaemic stress, in
parallel with increased tumorigenicity12. It is not yet known how
autophagy deficiency compromises genomic stability.
A seeming paradox is that autophagy, a pathway that functions
primarily in cell survival, also functions in tumour suppression
(Fig. 3), but two hypotheses have recently been proposed to explain
this paradox12. First, when tumour cells cannot die by apoptosis upon
exposure to metabolic stress, autophagy may prevent death by
necrosis, a process that might exacerbate local inflammation and
thereby increase tumour growth rate. Second, as noted above, even
though autophagy promotes cell survival in the setting of metabolic
stress in the tumour microenvironment, it acts concurrently to pre-
vent genomic instability. An additional possibility is that despite
its pro-survival effects, autophagy activation during metabolic stress
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(and high density conditions) prevents cell growth13. Although the
pro-survival effects of autophagy may often be counterbalanced by its
tumour suppressor effects, an area of growing interest is the potential
contribution of these pro-survival effects to tumour cell resistance to
chemotherapy; recent studies have shown that genetic or pharmaco-
logical inhibition of autophagy enhances cytoxicity of cancer che-
motherapeutic agents53,54. Consequently, clinical trials are in progress
(based on studies in mouse models55) to disrupt autophagic degra-
dation to maximize the effects of cancer cytotoxic agents. Thus, much
as in neurodegenerative and cardiac diseases, it may be necessary
to differentially target autophagy in a context-specific and disease-
stage-specific manner; autophagy augmentation may be effective in
preventing tumour formation and progression, whereas autophagy
inhibition may be helpful in promoting tumour regression.
Ageing and longevity
A common characteristic of all ageing cells is the accumulation of
damaged proteins and organelles, even in the absence of any muta-
tions that predispose the cells to a pathogenic phenotype such as
aggregate-prone mutant proteins (Fig. 4). As discussed above, these
deposits of altered components are particularly detrimental in non-
dividing differentiated cells, such as neurons and cardiomyocytes,
where the characteristic functional decline with age usually manifests
itself sooner than in other cell types. Both macroautophagy and CMA
activity decrease with age56,57. In light of the dramatic phenotypes
observed in the recently generated genetic mouse models with
impaired autophagy18,19,23,24, it is easy to infer that a gradual decrease
in autophagic activity with age could play a major role in the func-
tional deterioration of ageing organisms. Conversely, caloric restric-
tion, the only intervention known to slow down ageing, seems to
improve autophagy induction, possibly owing to lower levels of
insulin, an autophagy inhibitor (Fig. 2). Current efforts to prevent
or restore the decline in macroautophagy with age are aimed at
reproducing the observed beneficial effect of caloric restriction on
this pathway through the use of anti-lipolytic drugs (that mimic the
starvation state induced by caloric restriction)58.
Outlook
In the past decade there has been a tremendous advance in our
knowledge about the molecular mechanism of macroautophagy,
including the identification of many of the components of the pro-
tein machinery. By comparison, our understanding of regulation,
particularly the complex interplay of multiple stimulatory and inhi-
bitory inputs, is relatively limited. To manipulate autophagy for
therapeutic purposes, especially considering its dual capacity in cyto-
protection and cell death, we need to improve our understanding of
the various regulatory pathways.
In contrast to the rapid advance in the molecular dissection of
macroautophagy and growing information about its regulation and
its pathophysiological relevance, our understanding of other forms of
autophagy is still limited. Critical molecular players have been iden-





























Figure 4 | Autophagy and ageing. Defective lysosomal function has been
reported in almost all tissues of ageing organisms, from nematode worms to
mammals, and both macroautophagy and CMA activity decrease with age56.
Problems in the regulation and execution of macroautophagy contribute to
its functional decline during ageing57. Upregulation of macroautophagy by
increased levels of glucagon in serum (that is, between meals) is lost in older
organisms, possibly owing to persistently enhanced basal activity of the
insulin receptor in response to the higher content of reactive oxygen species
in ageing cells59. Also, accumulation of undigested material (lipofuscin)
inside secondary lysosomes (for example, autolysosomes) interferes with
their ability to fuse with autophagosomes and to degrade their cargo.
Changes with age in the lysosomal membrane make the CMA receptor
unstable. The age-dependent decrease in the levels of this receptor is
responsible for low CMA activity in older organisms60. Some predicted
consequences of the decline in autophagy with age are the inefficient
clearance of damaged components, a poor response to stress, and a possible
precipitating effect on disease.
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translocation systems, that other regulatory components are yet
to be discovered. The current available information about micro-
autophagy is even more limited and the absence of reliable markers
or assays to track this process has prevented any connection of micro-
autophagic changes with physiological or pathological conditions.
Although starvation or stress adaptation is an evolutionarily con-
served function of autophagy under physiological conditions, the
degradation of intracellular components may be a more important
function when considering the role of autophagy in disease. One area
of future interest is to study how autophagy functions in preventing
neurodegeneration, although at present we do not know the direct
cause of the toxicity of neuropeptides such as Ab and a-synuclein. In
addition, we need to understand the issue of functional autophagy
serving a protective role, as opposed to compromised autophagy
and the accompanying accumulation of cytosolic autophagosomes,
which contributes to pathogenesis in neurodegeneration, liver
disease and myopathies, because induction of autophagy in these
latter situations can exacerbate the disease pathology. Similarly, we
should carefully consider the type and progression of diseases such as
cancer when attempting to determine whether autophagy inhibition
or stimulation is likely to be beneficial. To understand immunity
better, it will be important to identify the mechanisms by which
autophagy is activated in response to microbial invasion, the targets
that allow specific recognition of intracellular pathogens, and the
roles of autophagy in immune cell function.
One of the current challenges in the study of autophagy in ageing is
that most of the genetic mouse models with impaired autophagy do
not reproduce the main characteristics of the ageing-dependent
changes. In these models there is complete blockage of autophagy
and this blockage is present from birth. The recent introduction of
conditional knockout mice should help in part to overcome this
problem, because these make it possible to compare the conse-
quences of impaired autophagy from birth, when compensatory
mechanisms are likely to be activated, with that occurring in the adult
organism.
Thus, although tremendous advances have been made in our
understanding of autophagy, many unanswered questions remain.
A fuller understanding of all types of autophagy is necessary before we
can hope to manipulate these pathways to treat human disease.
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